-
Analyst: The Nature Of TherapeuticsMD 's CRL From The FDA Is A 'Best-Case Scenario'
Tuesday, May 9, 2017 - 9:20am | 408Read More...On Monday, TherapeuticsMD Inc (NYSE: TXMD) received a Complete Response Letter from the FDA related to the company’s New Drug Application for TX-004HR. TX-004HR is a applicator-free estradiol vaginal softgel capsule used to treat moderate-to-severe sexual intercourse pain caused by vulvar and...
